AQR Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.54M | Buy |
78,778
+11,126
| +16% | +$272K | ﹤0.01% | 2520 |
|
|
2025
Q4 | $1.81M | Buy |
67,652
+5,507
| +9% | +$142K | ﹤0.01% | 2182 |
|
|
2025
Q3 | $1.66M | Sell |
62,145
-13,700
| -18% | -$354K | ﹤0.01% | 2101 |
|
|
2025
Q2 | $1.74M | Buy |
75,845
+22,207
| +41% | +$551K | ﹤0.01% | 1864 |
|
|
2025
Q1 | $1.55M | Buy |
53,638
+24,167
| +82% | +$772K | ﹤0.01% | 1751 |
|
|
2024
Q4 | $1.09M | Sell |
29,471
-12,196
| -29% | -$558K | ﹤0.01% | 1841 |
|
|
2024
Q3 | $2.02M | Sell |
41,667
-14,129
| -25% | -$620K | ﹤0.01% | 1502 |
|
|
2024
Q2 | $2.23M | Sell |
55,796
-1,258
| -2% | -$52.1K | ﹤0.01% | 1410 |
|
|
2024
Q1 | $2.51M | Buy |
57,054
+44,310
| +348% | +$2.29M | ﹤0.01% | 1310 |
|
|
2023
Q4 | $788K | Sell |
12,744
-16,246
| -56% | -$853K | ﹤0.01% | 1690 |
|
|
2023
Q3 | $1.33M | Sell |
28,990
-30,046
| -51% | -$1.64M | ﹤0.01% | 1496 |
|
|
2023
Q2 | $3.39M | Sell |
59,036
-51,851
| -47% | -$2.3M | 0.01% | 1060 |
|
|
2023
Q1 | $4.16M | Sell |
110,887
-1,716
| -2% | -$56.3K | 0.01% | 974 |
|
|
2022
Q4 | $3.16M | Buy |
112,603
+17,850
| +19% | +$518K | 0.01% | 1080 |
|
|
2022
Q3 | $2.66M | Buy |
94,753
+59,463
| +168% | +$1.94M | 0.01% | 1088 |
|
|
2022
Q2 | $1.23M | Buy |
35,290
+21,791
| +161% | +$778K | ﹤0.01% | 1326 |
|
|
2022
Q1 | $485K | Buy |
13,499
+2,924
| +28% | +$82.9K | ﹤0.01% | 1831 |
|
|
2021
Q4 | $246K | Sell |
10,575
-8,702
| -45% | -$178K | ﹤0.01% | 2031 |
|
|
2021
Q3 | $366K | Sell |
19,277
-591
| -3% | -$11.6K | ﹤0.01% | 1978 |
|
|
2021
Q2 | $401K | Sell |
19,868
-4,653
| -19% | -$87.7K | ﹤0.01% | 1965 |
|
|
2021
Q1 | $449K | Sell |
24,521
-12,125
| -33% | -$225K | ﹤0.01% | 1875 |
|
|
2020
Q4 | $737K | Sell |
36,646
-15,829
| -30% | -$308K | ﹤0.01% | 1638 |
|
|
2020
Q3 | $984K | Sell |
52,475
-23,498
| -31% | -$473K | ﹤0.01% | 1412 |
|
|
2020
Q2 | $1.71M | Sell |
75,973
-12,873
| -14% | -$236K | ﹤0.01% | 1229 |
|
|
2020
Q1 | $1.32M | Buy |
88,846
+50,278
| +130% | +$875K | ﹤0.01% | 1230 |
|
|
2019
Q4 | $744K | Sell |
38,568
-1,567
| -4% | -$30.1K | ﹤0.01% | 1611 |
|
|
2019
Q3 | $796K | Buy |
40,135
+21,632
| +117% | +$451K | ﹤0.01% | 1594 |
|
|
2019
Q2 | $391K | Sell |
18,503
-3,108
| -14% | -$65K | ﹤0.01% | 1808 |
|
|
2019
Q1 | $442K | Sell |
21,611
-492
| -2% | -$11K | ﹤0.01% | 1846 |
|
|
2018
Q4 | $440K | Sell |
22,103
-2,523
| -10% | -$49.7K | ﹤0.01% | 1823 |
|
|
2018
Q3 | $474K | Buy |
24,626
+4,963
| +25% | +$88.5K | ﹤0.01% | 1974 |
|
|
2018
Q2 | $300K | Sell |
19,663
-839
| -4% | -$14.7K | ﹤0.01% | 2120 |
|
|
2018
Q1 | $384K | Hold |
20,502
| – | – | ﹤0.01% | 1990 |
|
|
2017
Q4 | $394K | Sell |
20,502
-3,913
| -16% | -$73.1K | ﹤0.01% | 1990 |
|
|
2017
Q3 | $436K | Sell |
24,415
-41,495
| -63% | -$683K | ﹤0.01% | 1986 |
|
|
2017
Q2 | $1.18M | Sell |
65,910
-33,731
| -34% | -$535K | ﹤0.01% | 1612 |
|
|
2017
Q1 | $1.45M | Buy |
99,641
+6,912
| +7% | +$109K | ﹤0.01% | 1529 |
|
|
2016
Q4 | $1.71M | Sell |
92,729
-14,253
| -13% | -$277K | ﹤0.01% | 1479 |
|
|
2016
Q3 | $2.03M | Buy |
106,982
+67,270
| +169% | +$1.22M | ﹤0.01% | 1410 |
|
|
2016
Q2 | $640K | Buy |
39,712
+17,853
| +82% | +$252K | ﹤0.01% | 1784 |
|
|
2016
Q1 | $262K | Sell |
21,859
-5,391
| -20% | -$63.6K | ﹤0.01% | 2040 |
|
|
2015
Q4 | $388K | Buy |
27,250
+3,080
| +13% | +$40.7K | ﹤0.01% | 1964 |
|
|
2015
Q3 | $283K | Buy |
+24,170
| New | +$363K | ﹤0.01% | 1942 |
|
Other funds holding AMPH
VCM
BTW
AQR Capital Management's AMPH Position: Q1 2026 in Review
AQR Capital Management increased its Amphastar Pharmaceuticals (AMPH) stake by 16% in Q1 2026, buying an estimated $272K and bringing the position to 78,778 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2520.
AQR Capital Management first reported a position in AMPH in Q3 2015 and has held it in 43 quarters since. The position peaked at $4.16M in Q1 2023. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.
- AQR Capital Management held 78,778 shares of Amphastar Pharmaceuticals worth $1.54M as of Q1 2026.
- AQR Capital Management bought 11,126 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $272K.
- Amphastar Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2520 holding.
- AQR Capital Management first reported a position in Amphastar Pharmaceuticals in Q3 2015 and has held it in 43 quarters since.
- AQR Capital Management's Amphastar Pharmaceuticals position peaked at $4.16M in Q1 2023.
- 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.
Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.